Who
Albert D. Dyrness
Director
Company insider
Files Form 4 as: Director, Hyperliquid Strategies; Director, Sonnet BioTherapeutics Holdings; Director, Outlook Therapeutics.
In numbers
- Trades disclosed
- 15
- Buys
- 2
- Sells
- 0
- Bought
- $21K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 22 Dec 2016
- Last trade
- 9 Feb 2026
- Last filed
- 11 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Feb 2026filed 11 Feb 2026 | PURR Hyperliquid StrategiesDigital Asset Treasuries | SEC FORM 4 Code A | —40,789 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | PURR Hyperliquid StrategiesDigital Asset Treasuries | SEC FORM 4 Code A | —40,789 at $0.00 | filing |
| 2 Dec 2025filed 23 Dec 2025 | PURR Hyperliquid StrategiesDigital Asset Treasuries | SEC FORM 4 Code J | —882 | filing |
| 2 Dec 2025filed 3 Dec 2025 | Sonnet BioTherapeutics Holdings | SEC FORM 4 Code D | —4,537 | filing |
| 11 Dec 2023filed 5 Dec 2024 | Sonnet BioTherapeutics Holdings | SEC FORM 4 Code A | —373 | filing |
| 11 Jul 2023filed 15 Jul 2025 | Sonnet BioTherapeutics Holdings | SEC FORM 4 Code A | —4,000 | filing |
| 30 May 2023filed 31 May 2023 | Sonnet BioTherapeutics Holdings | SEC FORM 4 Bought | $11K23,255 at $0.47 | filing |
| 14 Dec 2022filed 22 Dec 2022 | Sonnet BioTherapeutics Holdings | SEC FORM 4 Code A | —3,770 | filing |
| 15 Dec 2021filed 8 Apr 2022 | Sonnet BioTherapeutics Holdings | SEC FORM 4 Code A | —14,152 | filing |
| 2 Jul 2020filed 2 Jul 2020 | Sonnet BioTherapeutics Holdings | SEC FORM 4 Code A | —8,005 at $0.00 | filing |
| 11 Jun 2020filed 12 Jun 2020 | Sonnet BioTherapeutics Holdings | SEC FORM 4 Bought | $9,6602,409 at $4.01 | filing |
| 1 Apr 2020filed 3 Apr 2020 | Sonnet BioTherapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —1,279 | filing |
| 1 Apr 2020filed 3 Apr 2020 | Sonnet BioTherapeutics Holdings | SEC FORM 4 Code A | —2,557 | filing |
| 26 Oct 2017filed 30 Oct 2017 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 22 Dec 2016filed 27 Dec 2016 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —11,500 | filing |
News
No headline names them, or the companies they trade most, lately.